{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:13:09Z","timestamp":1787170389668,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Optimal anticoagulation for pediatric acute liver failure (ALF) patients requiring continuous renal replacement therapy (CRRT) remains challenging due to concurrent bleeding risk and hypercoagulability. This study aimed to evaluate the efficacy and safety of various anticoagulation strategies in pediatric ALF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 51 children with ALF from January 2017 to December 2023. Patients were grouped based on anticoagulant: systemic heparin anticoagulation group (SHA group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919), regional citrate anticoagulation group (RCA group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915), and nafamostat mesylate group (NM group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917). Primary outcomes were filter lifespan and the incidence of new clinical bleeding episodes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Filter lifespan was shortest in the SHA group but similar between the RCA and NM groups [SHA: 37.0 [34.0, 42.0] h; RCA: 43.0 [39.0, 49.0] h; NM: 43.0 [40.5, 48.0] h;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003]. The SHA group experienced a significantly higher rate of new bleeding episodes (36.8%) compared with the RCA (6.7%) and NM (5.9%) groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.036). Metabolic alkalosis and hypocalcemia were more frequent in the RCA group (46.7% vs. 10.5% vs. 11.8%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Multivariate Cox regression showed that, relative to SHA, both RCA and NM significantly reduced filter clotting risk (HR\u2009=\u20090.108, 95% CI 0.047\u20130.248,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Additionally, higher pre-CRRT platelet count (HR\u2009=\u20091.014, 95% CI 1.007\u20131.021,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), and higher initial transmembrane pressure (HR\u2009=\u20091.168, 95% CI 1.104 \u22121.236,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) were associated with increased clotting risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In ALF children undergoing CRRT, both RCA and NM demonstrate superior filter longevity and bleeding safety compared to heparin. NM may be preferred due to fewer metabolic disturbances than RCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1667760","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T05:28:15Z","timestamp":1756186095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of different anticoagulation methods in continuous renal replacement therapy for pediatric acute liver failure patients: a retrospective observational study"],"prefix":"10.3389","volume":"13","author":[{"given":"Jie","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s12072-022-10417-5","article-title":"Etiology, outcome and prognostic indicators of acute liver failure in Asian children","volume":"16","author":"Ng","year":"2022","journal-title":"Hepatol Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1097\/MPG.0000000000003448","article-title":"Outcomes analyses of pediatric acute liver failure subjects listed for liver transplantation","volume":"74","author":"Kulkarni","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/MPG.0000000000001178","article-title":"Outcomes of children with and without hepatic encephalopathy from the pediatric acute liver failure study group","volume":"63","author":"Ng","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1007\/s00431-024-05587-3","article-title":"Continuous renal replacement therapy and therapeutic plasma exchange in pediatric liver failure","volume":"183","author":"Jackson","year":"2024","journal-title":"Eur J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"154513","DOI":"10.1016\/j.jcrc.2023.154513","article-title":"Continuous renal replacement therapy and survival in acute liver failure: a systematic review and meta-analysis","volume":"81","author":"Dong","year":"2024","journal-title":"J Crit Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"618119","DOI":"10.3389\/fped.2020.618119","article-title":"Hemostatic balance in pediatric acute liver failure: epidemiology of bleeding and thrombosis, physiology, and current strategies","volume":"8","author":"Bulut","year":"2020","journal-title":"Front Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.rgmxen.2023.08.008","article-title":"Guidelines for the management of coagulation disorders in patients with cirrhosis","volume":"89","author":"Aiza-Haddad","year":"2024","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1159\/000540302","article-title":"A comparison of the anticoagulation efficacy and safety of epoprostenol to heparin and citrate in children receiving continuous renal replacement therapy","volume":"53","author":"Sondhi","year":"2024","journal-title":"Blood Purif"},{"key":"B9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12882-024-03506-0","article-title":"Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study","volume":"25","author":"Kameda","year":"2024","journal-title":"BMC Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/PCC.0000000000003371","article-title":"Epoprostenol (prostacyclin analog) as a sole anticoagulant in continuous renal replacement therapy for critically ill children with liver disease: single-center retrospective study, 2010\u20132019","volume":"25","author":"Deep","year":"2024","journal-title":"Pediatr Crit Care Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41390-024-03163-x","article-title":"Citrate anticoagulation and systemic heparin anticoagulation during continuous renal replacement therapy among critically-ill children","volume":"96","author":"Atis","year":"2024","journal-title":"Pediatr Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/03913988241269492","article-title":"Regional citrate anticoagulation versus LMWH anticoagulation for CRRT in liver failure patients without increased bleeding risk","volume":"47","author":"Tang","year":"2024","journal-title":"Int J Artif Organs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2215\/CJN.08430520","article-title":"Anticoagulation strategies and filter life in COVID-19 patients receiving continuous renal replacement therapy: a single-center experience","volume":"16","author":"Shankaranarayanan","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13054-023-04519-1","article-title":"Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials","volume":"27","author":"Zhou","year":"2023","journal-title":"Crit Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD12467","DOI":"10.1002\/14651858.CD012467.pub3","article-title":"Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy","volume":"12","author":"Tsujimoto","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2215\/CJN.0000000000000390","article-title":"Citrate anticoagulation for CKRT with liver failure: ready for prime time?","volume":"19","author":"Szamosfalvi","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10760296231174001","DOI":"10.1177\/10760296231174001","article-title":"Regional citrate anticoagulation or heparin anticoagulation for renal replacement therapy in patients with liver failure: a systematic review and meta-analysis","volume":"1299611791","author":"Qi","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"B18","doi-asserted-by":"publisher","first-page":"847443","DOI":"10.3389\/fped.2022.847443","article-title":"Clinical application of regional citrate anticoagulation for continuous renal replacement therapy in children with liver injury","volume":"10","author":"Hu","year":"2022","journal-title":"Front Pediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2022.07.022","article-title":"Anticoagulation with nafamostat mesilate during extracorporeal life support","volume":"366","author":"Lang","year":"2022","journal-title":"Int J Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"B21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/MPG.0000000000003268","article-title":"North American society for pediatric gastroenterology, hepatology, and nutrition position paper on the diagnosis and management of pediatric acute liver failure","volume":"74","author":"Squires","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/PEC.0000000000000884","article-title":"Acute liver failure: outcome and value of pediatric end-stage liver disease score in pediatric cases","volume":"34","author":"N\u00fa\u00f1ez-Ramos","year":"2018","journal-title":"Pediatr Emerg Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s13054-015-1066-7","article-title":"Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the liver citrate anticoagulation threshold (L-CAT) observational study","volume":"19","author":"Slowinski","year":"2015","journal-title":"Crit Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13054-019-2317-9","article-title":"Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis","volume":"23","author":"Zhang","year":"2019","journal-title":"Crit Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2215\/CJN.0000000000000351","article-title":"Regional citrate anticoagulation versus no anticoagulation for CKRT in patients with liver failure with increased bleeding risk","volume":"19","author":"Bai","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"fmac048","DOI":"10.1093\/tropej\/fmac048","article-title":"Continuous renal replacement therapy with regional citrate anticoagulation in children with liver dysfunction\/failure","volume":"68","author":"Botan","year":"2022","journal-title":"J Trop Pediatr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13054-017-1870-3","article-title":"Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction","volume":"21","author":"Klingele","year":"2017","journal-title":"Crit Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13054-020-2801-2","article-title":"In severe liver disease, citrate can be used safely: the question remains\u2014by which mechanism","volume":"24","author":"Honore","year":"2020","journal-title":"Crit Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40001-024-01660-7","article-title":"Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study","volume":"29","author":"Liu","year":"2024","journal-title":"Eur J Med Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/jbcr\/irad196","article-title":"Filter lifespan, treatment effect, and influencing factors of continuous renal replacement therapy for severe burn patients","volume":"45","author":"Yue","year":"2024","journal-title":"J Burn Care Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/1744-9987.13958","article-title":"Characteristics of pediatric continuous renal replacement therapies in hospitals with pediatric intensive care units in Japan","volume":"27","author":"Haga","year":"2023","journal-title":"Ther Apher Dial"},{"key":"B32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4266\/acc.2021.01312","article-title":"The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation","volume":"37","author":"Lee","year":"2022","journal-title":"Acute Crit Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s00467-022-05502-8","article-title":"Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy","volume":"37","author":"Miyaji","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/0886022X.2022.2105233","article-title":"Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis","volume":"44","author":"Lin","year":"2022","journal-title":"Ren Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/MAT.0000000000001681","article-title":"Impact of continuous renal replacement therapy on bivalirudin dosing in pediatric extracorporeal membrane oxygenation","volume":"68","author":"Lahart","year":"2022","journal-title":"ASAIO J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"CD13330","DOI":"10.1002\/14651858.CD013330.pub2","article-title":"Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy","volume":"9","author":"Tsujimoto","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/1744-9987.14024","article-title":"Factors affecting continuous renal replacement therapy duration in critically ill patients: a retrospective study","volume":"27","author":"Guo","year":"2023","journal-title":"Ther Apher Dial"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1007\/s00467-024-06459-6","article-title":"Factors influencing circuit lifetime in paediatric continuous kidney replacement therapies\u2014results from the EurAKId registry","volume":"39","author":"Deja","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/s1441-2772(23)01477-1","article-title":"Filter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables","volume":"16","author":"Dunn","year":"2014","journal-title":"Crit Care Resusc"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00467-017-3601-z","article-title":"Membrane pressures predict clotting of pediatric continuous renal replacement therapy circuits","volume":"32","author":"Kakajiwala","year":"2017","journal-title":"Pediatr Nephrol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1667760\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T05:28:16Z","timestamp":1756186096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1667760\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":40,"alternative-id":["10.3389\/fped.2025.1667760"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1667760","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"1667760"}}